Navigation Links
Bio-Rad Initiates Long Term Financial Guidance; Commits to Defining Long Term Capital Allocation Targets and Hosting an Annual Investor Day
Date:3/13/2017

HERCULES, Calif., March 13, 2017 /PRNewswire/ -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, today announced several significant strategic priorities, including initiating long term financial guidance, commitment to defining new capital allocation targets, and hosting an annual Investor Day later this year.

Bio-Rad expects to achieve the following financial results for revenue and EBITDA margins:

  • Long-term currency-neutral revenue growth of approximately 3% to 5%
  • Currency-neutral EBITDA margin of greater than 20% by 2020

Bio-Rad will provide further details on its long term revenue growth and profitability goals based on this EBITDA margin target. 

Bio-Rad also plans to define a prudent capital allocation policy focused on maximizing value over the long-term. The Company commits to evaluate leverage levels that will enable Bio-Rad to maintain its strong balance sheet and investment grade credit ratings, while providing flexibility to opportunistically pursue organic growth initiatives and attractive bolt-on acquisitions. Should Bio-Rad identify compelling strategic opportunities that take the Company above this target, management is committed to de-levering back to the target range over time. Given its excess cash position, Bio-Rad intends to move to its target leverage ratio through share repurchases and/or value-creating M&A.

Bio-Rad plans to hold an Investor Day later this year, during which management will discuss the Company's operating performance, organic and inorganic growth priorities and capital allocation strategy.

Norman Schwartz, Bio-Rad Chairman and Chief Executive Officer, commented: "Today marks an important step forward for Bio-Rad. As we cycle through investments designed to enhance our growth and improve our operating efficiency, we are striving to achieve EBITDA margins that will create significant stockholder value over the long-term. We are committed to improving communication with the investor and analyst community as well as actively pursuing additional sell-side coverage."

Reiterates 2017 Financial Outlook

Bio-Rad also reiterated its 2017 financial outlook and continues to anticipate currency neutral revenue growth of approximately 4 percent, and improved profitability with a currency neutral GAAP operating margin of 7 percent for the full year 2017. As previously discussed, guidance includes elevated operating costs due to the implementation of Bio-Rad's ERP system. Revenue and operating margin guidance does not include the impacts of the recent acquisition of RainDance.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The Company employs more than 8,250 people worldwide and had revenues exceeding $2 billion in 2016. For more information, please visit www.bio-rad.com.

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "intends," "believes," "expects," "anticipates," "may," "will,"  "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad's public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.

Contacts

Christine Tsingos, Executive Vice President and Chief Financial Officer
Bio-Rad Laboratories, Inc.
510-741-6006
investor_relations@bio-rad.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bio-rad-initiates-long-term-financial-guidance-commits-to-defining-long-term-capital-allocation-targets-and-hosting-an-annual-investor-day-300422383.html


'/>"/>
SOURCE Bio-Rad Laboratories, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. New Products, Price Movements, and Leadership Appointments - Research Report on Waters, Cognex, Fluidigm, Cepheid, and Bio-Rad
2. Global Digital PCR (dPCR) Market 2015-2019 with Bio-Rad Laboratories, Fluidigm, RainDance Technologies & Thermo Fisher Scientific Dominating
3. Global ADME-Toxicology Testing Market 2015-2019 - Advances in Technology with Accelrys, Agilent Technologies, Bio-Rad Laboratories, Promega, Sigma Aldrich & Thermo Fisher Scientific Dominating
4. Global Microfluidics Market Report 2015-2020 Featuring Danaher, Thermo Fisher Scientific, Becton, Dickinson and Co, Agilent Technologies, Bio-Rad Laboratories & PerkinElmer
5. Digital PCR (dPCR) and qPCR Market to 2019 - With Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc and F. Hoffmann-La Roche Ltd Dominating the Market
6. Global In-Vitro Diagnostics Packaging Market 2016-2020 - Leading Vendors are Bio-Rad, Corning, Greiner Bio-One & Narang Medical
7. Global Label-Free Detection Market Value of USD 2.13 Billion by 2020 - Analysis, Trends & Opportunities 2016-2020 - Key Vendors: Attana AB, Bio-Rad & Danaher
8. Research and Markets - Global Chromatography Market 2016-2020 with Agilent Technologies, Bio-Rad Laboratories, Shimadzu & Thermo Fisher Scientific Dominating
9. Research and Markets - General Surgery Devices Market to Reach $17 Billion by 2024, with Abbott Laboratories, Danaher Corporation & Bio-Rad Labs Dominating
10. AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy
11. Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2019)... ... 2019 , ... LuckyVitamin, an e-commerce specialty retailer and manufacturer ... Healthiest Employers of 2019. LuckyVitamin’s Founder and Chief Wellness Spreader, Sam Wolf, along ... at the Ballroom at the Ben on June 13, 2019. , This highly ...
(Date:6/19/2019)... ... 19, 2019 , ... Advocates for Physicians’ Rights (AFPR), a ... protection of physicians’ rights, asserts that the recent SB 276 Amendments encroach on ... narrow guidelines as a basis for issuing legitimate medical exemptions. , “The ...
(Date:6/19/2019)... OBISPO, Calif. (PRWEB) , ... June 19, 2019 , ... “We sometimes take out teeth ... and flossing, and regular checkups we seldom think about our teeth unless it’s baby’s first ... teeth help us chew, speak, smile and have a very important role in our overall ...
Breaking Medicine Technology:
(Date:6/24/2019)... ... 2019 , ... Cibo Vita, Inc., makers of Nature’s Garden, NutriPops, Chocolate Orchard ... indulgence snack line at the 65th annual Summer Fancy Food Show, taking place at ... booth #5721. , The company’s expansive product portfolio features a variety of trail ...
(Date:6/20/2019)... ... , ... Access Healthcare, one of the largest providers of ... appointed as Senior Vice President of Client Services. Angel brings more than 20 ... high performing teams, and driving revenue growth for healthcare companies. , In this ...
(Date:6/19/2019)... (PRWEB) , ... June 19, ... ... from non-governmental organizations, academia, faith-based organizations, private institutions, media, and government joined ... DC to make commitments to improve universal access to water, sanitation, and ...
(Date:6/19/2019)... , ... June 19, 2019 , ... A legal-medical ... the United States, has filed class action lawsuits in 34 of the 48 ... in the class actions are an array of pharmaceutical manufacturers, distributors and retailers, all ...
(Date:6/19/2019)... ... June 19, 2019 , ... Ovation® Fertility scientists have been invited ... Reproduction and Embryology (ESHRE) Annual Meeting in Vienna, June 23-26, 2019. , Ovation’s ... consideration for both the Basic Science Award for Oral Presentation and the Fertility Society ...
Breaking Medicine News(10 mins):